Efficacy and safety of Tocilizumab, plasmapheresis and their combination in severe COVID-19: A randomized clinical trial

This publication has 31 references indexed in Scilit:

• COVID-19 pathophysiology: A review
  Clinical Immunology, 2020
• Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19
  New England Journal of Medicine, 2020
• Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages
  Nature Reviews Immunology, 2020
• Tocilizumab treatment in COVID‐19: A single center experience
  Journal of Medical Virology, 2020
• Pathological findings of COVID-19 associated with acute respiratory distress syndrome
  The Lancet Respiratory Medicine, 2020
• Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
  The Lancet, 2020
• Interleukin-6 receptor inhibition with tocilizumab induces a selective and substantial increase in plasma IP-10 and MIP-1β in non-ST-elevation myocardial infarction
  International Journal of Cardiology, 2018
• Lectin Affinity Plasmapheresis for Middle East Respiratory Syndrome-Coronavirus and Marburg Virus Glycoprotein Elimination
  Blood Purification, 2018
• Risk of Tuberculosis Reactivation in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Receiving Non-Anti-TNF-Targeted Biologics
  Mediators of Inflammation, 2017
• SARS: pharmacotherapy
  Respirology, 2003